The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic ProgramsNEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr.

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.

The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...

Kodiak Sciences Inc.’s KOD share price has dipped by 10.63%, which has investors questioning if this is right time to buy.

The mean SHR in the group was 2.9 overall, but NVG patients had a significantly higher mean SHR (3.2) than non-NVG patients (2.7 ... ratio and neovascular glaucoma risk in proliferative diabetic ...

Of the 362 eyes with diabetes, 172 (48%) eyes were mild non-proliferative diabetic retinopathy (NPDR), 41 (11%) eyes were moderate NPDR, and 27 (7%) eyes were severe NPDR. Although previous works had ...

We will only include studies that refer to some measure of diabetic retinopathy treatment coverage in the abstract. As the use of anti-VEGF agents in the treatment of proliferative diabetic ...

Introduction There is growing evidence of a higher than expected prevalence of retinopathy in prediabetes. This paper presents the protocol of a systematic review and meta-analysis of retinopathy in ...

Company management will be available for one-on-one meetings during the conference. If you are interested in arranging a meeting, please contact your conference representative or send an email to ...